Symbols

IKNA

Ikena Oncology

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IKNA

Ikena Oncology, Inc.

A targeted oncology company that develops precision medicines tailored to biomarker-defined patient groups

Industry

Biological Technology

Established Date

03/02/2016

Listing Date

03/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ikenaoncology.com

Security Type

Common stock

Office address

645 Summer Street, Suite 101, Boston, MA 02210

Business

Introduction

Ikena Oncology, Inc., was incorporated as a Delaware corporation on March 2, 2016 and is headquartered in Boston, Massachusetts. The company is a targeted oncology company focused on developing novel cancer therapies targeting the critical signaling pathways that drive cancer formation and spread. The company's projects focus on key cancer-driven pathways that are well validated in the scientific literature but lack approved or effective treatments, and thus have the potential to address highly unmet medical needs. By leveraging a deep understanding of discovery chemistry, translational science and patient-centered drug development, the company has established an in-depth pipeline of wholly owned and partnered projects focused on gene-defined or biomarker-driven cancers, able to target specific patient groups that the company believes are most likely to respond to the treatment of product candidates. Since commencing operations in 2016, the company has discovered or developed five oncology programs, including four product candidates in IND research or clinical development.

Company Financials

EPS

IKNA has released its 2024 Q3 earnings. EPS was reported at -0.21, versus the expected -0.27, beating expectations. The chart below visualizes how IKNA has performed over recent quarters, highlighting trends in earnings surprises.